These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7594094)

  • 21. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy.
    Yokoyama I; Momomura S; Ohtake T; Yonekura K; Yang W; Kobayakawa N; Aoyagi T; Sugiura S; Yamada N; Ohtomo K; Sasaki Y; Omata M; Yazaki Y
    Circulation; 1999 Jul; 100(2):117-22. PubMed ID: 10402439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous transluminal coronary angioplasty reverses vasoconstriction of stenotic coronary arteries in hypertensive patients.
    Frielingsdorf J; Kaufmann P; Suter T; Hug R; Hess OM
    Circulation; 1998 Sep; 98(12):1192-7. PubMed ID: 9743510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise-induced coronary artery vasodilation is not impaired by stent placement.
    Maier W; Windecker S; Küng A; Lütolf R; Eberli FR; Meier B; Hess OM
    Circulation; 2002 May; 105(20):2373-7. PubMed ID: 12021223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
    Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
    Togni M; Windecker S; Cocchia R; Wenaweser P; Cook S; Billinger M; Meier B; Hess OM
    J Am Coll Cardiol; 2005 Jul; 46(2):231-6. PubMed ID: 16022947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise.
    Gordon JB; Ganz P; Nabel EG; Fish RD; Zebede J; Mudge GH; Alexander RW; Selwyn AP
    J Clin Invest; 1989 Jun; 83(6):1946-52. PubMed ID: 2723067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate.
    Meco JF; Vila R; Pujol R; Bros R; Domènech P; Fiol C; Pintó X
    J Cardiovasc Pharmacol; 2001 Aug; 38(2):250-8. PubMed ID: 11483875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of intracoronary and intravenous propranolol on human coronary arteries.
    Hess OM; Bortone A; Gaglione A; Nonogi H; Grimm J; Krayenbuehl HP
    Eur Heart J; 1989 Nov; 10 Suppl F():153-8. PubMed ID: 2620682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal coronary vasomotion during exercise in patients with normal coronary arteries and reduced coronary flow reserve.
    Bortone AS; Hess OM; Eberli FR; Nonogi H; Marolf AP; Grimm J; Krayenbuehl HP
    Circulation; 1989 Mar; 79(3):516-27. PubMed ID: 2492909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Abnormal coronary vasomotility in subjects with normal coronary arteries and reduced reserve of coronary flow].
    Bortone A; Hess OM; Gaglione A; Locuratolo N; Musci S; Sebastiani M; Rizzon P; Chiddo A
    Cardiologia; 1989 Jan; 34(1):33-46. PubMed ID: 2720712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia.
    Igarashi K; Tsuji M; Nishimura M; Horimoto M
    J Clin Apher; 2004; 19(1):11-6. PubMed ID: 15095396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries.
    Hamasaki S; Higano ST; Suwaidi JA; Nishimura RA; Miyauchi K; Holmes DR; Lerman A
    Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):737-43. PubMed ID: 10712399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
    Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
    Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary collateral flow in response to endurance exercise training.
    Zbinden R; Zbinden S; Meier P; Hutter D; Billinger M; Wahl A; Schmid JP; Windecker S; Meier B; Seiler C
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):250-7. PubMed ID: 17446804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study.
    Ohsawa H; Uchida Y; Fujimori Y; Hirose J; Noike H; Tokuhiro K; Kawamura K; Kanai M; Sakuragawa H; Hitsumoto T; Aoyagi K; Sakurai T; Sato S; Yoshinaga K; Kaku M; Ozegawa M; Morio H; Yamada K; Terasawa K; Uchida Y; Ohshima T
    Jpn Heart J; 2002 Jul; 43(4):319-31. PubMed ID: 12227708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of exercise on coronary endothelial function in patients with coronary artery disease.
    Hambrecht R; Wolf A; Gielen S; Linke A; Hofer J; Erbs S; Schoene N; Schuler G
    N Engl J Med; 2000 Feb; 342(7):454-60. PubMed ID: 10675425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study].
    Sinzinger H; Virgolini I; Kudlacek P
    Wien Klin Wochenschr; 1991; 103(13):381-7. PubMed ID: 1897230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
    Treasure CB; Klein JL; Weintraub WS; Talley JD; Stillabower ME; Kosinski AS; Zhang J; Boccuzzi SJ; Cedarholm JC; Alexander RW
    N Engl J Med; 1995 Feb; 332(8):481-7. PubMed ID: 7830728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.